Trial Profile
Phase I Study of Oral Guanabenz for Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2017
Price :
$35
*
At a glance
- Drugs Guanabenz (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 31 Oct 2017 Status changed from recruiting to discontinued.
- 15 Feb 2017 Planned End Date changed from 20 Jan 2017 to 20 Jan 2018.
- 15 Feb 2017 Planned primary completion date changed from 20 Jan 2019 to 20 Jan 2018.